Advertisement
Advertisement
AAPG
Ascentage Pharma Group International - ADR
15.43
USDSponsored
+0.30
+1.98%
Nov 06, 15:59 UTC -5
Closed
After-Market
15.30
-0.13
-0.81%
Ascentage Pharma Group International - ADR (AAPG) Earnings
AAPG Earnings Reports
Positive Surprise Ratio
No Data Available for AAPG
0%
Next Report
Date of Next Report
Mar 25, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$1.78
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Ascentage Pharma Group International - ADR earnings per share and revenue
On Aug 19, 2026, AAPG reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -0.93% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -1.78 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Ascentage Pharma Group International - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ascentage Pharma Group International - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Ascentage Pharma Group International - ADR's Q2 2026 earnings?
The stock price moved down -0.93%, changed from $18.20 before the earnings release to $18.03 the day after.
When is Ascentage Pharma Group International - ADR expected to report next?
The next earning report is scheduled for Mar 25, 2027.
What are the forecasts for Ascentage Pharma Group International - ADR's next earnings report?
Based on --
analysts, Ascentage Pharma Group International - ADR is expected to report EPS of -$1.78 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.